Objective. This study aimed to evaluate the therapeutic efficacy of a novel polymer platform delivering cisplatin and cytokines in the treatment of head and neck squamous cell carcinoma (HNSCC).
Introduction
Patients with head and neck squamous cell carcinoma (HNSCC) are at considerable risk of mortality, with more than 300,000 deaths attributable to the disease annually. 1, 2 During the past 30 years, the 3-to 5-year survival rate of patients with advanced T3 and T4 HNSCC has remained poor (20%-30%) despite considerable advances in surgical techniques and irradiation delivery and improvement in chemotherapeutic strategies. Because 50% of the patients with advanced and unresectable disease fail primary management, salvaging these patients is of paramount importance. 3 Many of these patients receive radiation (RT) as definitive or as adjuvant therapy, which makes retreatment a challenge. Currently, the standard of care for recurrent disease is surgical salvage. It is unfortunate that many advanced head and neck cancers are unresectable due to their proximity to vital structures such as the carotid artery or the skull base. Although palliation by chemotherapy is often attempted, systemic toxicity and its effect on the quality of life of patients prevents its wider clinical application. 4 Given these dismal figures, new advances are needed in the effective treatment of HNSCC.
The science of polymer technology for drug delivery has evolved considerably since 1990. 5 Polymers have been developed to deliver different types of drugs, including anticancer agents and antibiotics. 6, 7 Because most head and neck cancers and their cervical metastatic nodes are clinically accessible, local treatment with a polymer matrix may have significant clinical applications.
We have developed a novel modular drug delivery device that reproducibly reduces tumor growth in vivo. 8 In this study, we have used a partial tumor resection model in the mouse, replicating the difficult situation that we see in our patients in which the entire tumor is not resectable. The polymer platform we have developed is a flexible sheet that is designed to be applied intraoperatively to the surgical bed after removing or debulking the tumor and is engineered to adapt and adhere to the surgical resected tissue contours. Cisplatin has been widely used in combination with radiation as a radiosensitizer in preclinical and clinical studies. 7 We hypothesized that the local delivery of cisplatin is expected to maximize therapeutic index, minimize systemic side effects, and enhance postoperative radiation treatment.
Another attractive addition to our modular platform is the concept of polymer delivery of immunomodulators, which will increase the efficiency of tumor cell killing by the host's immune system. Patients with HNSCC have been well documented to exhibit local immunosuppression with depressed T-cell-mediated responses as well as depressed natural killer (NK) cell and antibody-dependent cell cytotoxic effects. 9 C-C motif cytokine ligand 21 (CCL21) is an immune active chemokine involved in immune cell chemotaxis by binding to its CCR7 receptor. 10 Our group previously reported that CCL21 immunotherapy mediates T-celldependent anti-tumor effect and reduces tumor burden in a lung cancer model. Both innate NK and specific T-cell antitumor responses are significantly increased following dendritic cell (DC)-based CCL21 therapy.
Despite various approaches, gene therapy still has been limited significantly. 11 The role of cytokines in tumor regression is now well established. 12 The major limitation for the clinical use of cytokines is the lack of a simple and effective protocol for the local and sustained delivery of cytokines to the tumor milieu. We hypothesized that our polymer platform system would provide a safer and simpler alternative to current cytokine immunotherapies designed to deliver cytokines into the tumor microenvironment in a sustained manner. After resection of oral or head and neck cancer, the surgeon frequently finds a situation where part of the tumor is judged to be unresectable (eg, because of involvement of the carotid artery, skull base, prevertebral fascia, or the like). In these cases, implanting the polymer system in proximity to the tumor may provide benefit to these patients by increasing the dosage of local radiation and by serving as a platform for immunomodulation/drug therapy.
Methods

Polymer Fabrication
The cisplatin-releasing polymer was designed to be adequately flexible to adapt to irregular tissue contours without tearing. A 70:30 ratio of PLCL:PCL (poly[e-caprolactone]/ poly[e-caprolactone-co-lactide]) was found to offer the optimal flexibility. Both PCL and PLCL were obtained from Boehringer Ingelheim (Ingelheim am Rhein, Germany) and are manufactured under good manufacturing practices and International Organization for Standardization-certified facilities, qualifying these materials' availability for future clinical testing. 13 Cisplatin (4 mg/kg) was added to the polymer solution. For the DC-CCL21 delivery, fibrinogen (5 ug/mL) and thrombin (5 IU/mL) were dissolved in phosphate buffered saline and 100 mM CaCL 2 , respectively. A 1.5 3 1.5 cm 2 well was made of fibrin gel on top of the PCL-PLCL film for cell seeding. Material selection was limited to those that are used in US Food and Drug Administration (FDA)-approved devices.
Mouse Model
The mice used in this study were 6-week-old C3H/HeJ mice (The Jackson Laboratory, Bar Harbor, Maine, USA). Animals were maintained in the UCLA vivarium according to National Institutes of Health guidelines, and all procedures were conducted under institutionally approved animal protocols.
Animal Model Surgical Procedure
Four 3 10 5 cells from the well-established C3H/HeJ mouse SCCA cell line SCCVII/SF 14 were injected into the flanks of 6-week-old C3H/HeJ mice. Eight mice were injected in each group. Tumor growth was assessed 3 times per week. When tumors reached an average size of 0.5 to 1 cm 3 , all animals underwent surgery to debulk their tumors by 50% to approximate the surgical situation when a patient's tumor is unresectable and some tumor is left behind prior to polymer therapy. Skin flaps were elevated and the wound closed with sutures over the polymer sheet. Animals were then randomly assigned to the different treatment groups: (1) no polymer, (2) plain polymer, (3) plain polymer with local cisplatin injection, or (4) cisplatin polymer. For cytokine studies, mice were grouped into (1) no polymer, (2) plain polymer, (3) plain polymer with intratumoral injection of recombinant CCL21 twice a week, (4) polymer containing parental dendritic cells, or (5) polymer containing dendritic cells secreting CCL21 (DC-CCL21). Each group consisted of 8 mice for a total of 32 or 40 mice in each of the experimental sets above, and each experiment was performed in triplicate.
Radiation Therapy
For the RT experiments, the treatment groups were (1) no treatment (no polymer addition, surgical debulking only);
(2) no treatment (no polymer addition, surgical debulking only) 1 RT; (3) cisplatin polymer alone; and (4) cisplatin polymer 1 RT. Tumors were irradiated with a total dose of 16 Gy given in 4 Gy fractions on 4 consecutive days on postoperative days 1 to 4.
Enzyme-Linked Immunosorbent Assay
C-C motif cytokine ligand 21 concentrations were determined by enzyme-linked immunosorbent assay (ELISA) as recommended by the manufacturer (R&D Systems, Minneapolis, Minnesota, USA). The plates were incubated with avidin peroxidase. The subsequent change in color was read at 450 nm with a Microplate Reader (Molecular Dynamics, Sunnyvale, California, USA).
Western Blot
Tumor samples were lysed in modified radioimmunoprecipitation assay (RIPA) buffer. Proteins were resolved on polyvinylidene difluoride (PVDF) membranes (Millipore, Bedford, California, USA). The membranes were probed with E-cadherin, beta-catenin, gamma-catenin, vimentin, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), or tubulin antibodies (BD Biosciences, San Jose, California, USA) at 1:5000 dilution. Quantitative analysis was performed by ImageJ software (National Institutes of Health, Bethesda, Maryland, USA).
Flow Cytometry
Tumor leukocytes were isolated by digesting tumor tissue in collagenase IV (Sigma, St Louis, Missouri, USA). Flow cytometric analyses were performed on a FACScan flow cytometer (Becton Dickinson, San Jose, California, USA) in the UCLA JCCC Flow Cytometry Core Facility.
Statistics
Tumor volume was compared between groups with a 2-way analysis of variance (ANOVA) model containing terms for cisplatin polymer and radiation. In both types of tumor models, the log transformation was used to reduce the influence of outliers. P \ .05 was considered significant.
Results
Cisplatin-Secreting Polymer Reduces Tumor Burden in Head and Neck Cancer
We had previously published that this polymer device is safe and biocompatible in the animal model and is facile for surgical use. 8 We evaluated the antitumor efficacy of the chemotherapeutic layer of the polymer platform in murine models of head and neck cancer. Our results using this novel polymer platform demonstrate a significant reduction in tumor growth. The cisplatin-secreting polymer effectively reduced SCCVII/SF tumors in the C3H/HeJ mice by more than 10-fold on day 25 (P \ .01) ( Figure 1 ) as compared to control (surgical debulking only). We were able to confirm this decrease in tumor burden by excising the tumors that had been treated with the cisplatin polymer ( Figure 1) . Our data show that our cisplatinsecreting polymer is more effective against head and neck cancer than the plain polymer plus cisplatin given as an intratumoral bolus injection. In addition, mice treated with radiation, with or without cisplatin polymer implantation, demonstrated significant reduction in tumor regrowth compared to the control group. 8 These results are quite promising that the polymer platform can direct the highest dose of radiation therapy to the tumor and spare surrounding normal tissues. 8 Dendritic Cells Overexpressing CCL21 (DC-CCL21) Can Grow and Successfully Secrete CCL21 from the Polymer To investigate the biocompatibility of our polymer in culturing DCs in vitro, we initially investigated the capacity of DCs to grow and survive in vitro while in the polymer. Cells were plated at different initial densities within the polymer or directly onto plates (without the polymer) in vitro. Five days later, DCs in the 10 6 /well group grew to 2 3 10 6 in the polymer or to 3 3 10 6 without polymer (Figure 2A) . Although we noted a less robust growth rate in the DC-polymer group, DC grown in the polymer exhibited similar morphology as those cultured without polymer.
To investigate the efficacy of CCL21 production from polymer-cultured DCs (DC-CCL21), ELISA was performed on medium collected from the in vitro plates after 5 days of culture. Time-dependent experiments demonstrated continuous release of CCL21 from 10 5 DCs ( Figure 2B) . Our data revealed a reproducible correlation between initial cell density and final CCL21 production ( Figure 2C) . The maximum yield of CCL21 was 2058 6 203 pg/mL from 10 6 cells over 5 days, and this is therefore the dose that we used in all subsequent experiments.
DC-CCL21 Secreting Polymer Reduces Tumor Burden in Head and Neck Cancer
We evaluated the antitumor efficacy of the DC-CCL21 polymer platform in murine models of head and neck cancer. Our results using this novel polymer platform demonstrate a significant reduction in tumor growth. Animals were randomly assigned to the following 5 treatment groups: (1) no polymer, (2) plain polymer, (3) plain polymer with intratumoral injection of recombinant CCL21 twice a week, (4) polymer containing parental dendritic cells, or (5) polymer containing dendritic cells secreting CCL21 (DC-CCL21).
The DC-CCL21 secreting polymer effectively reduced SCCVII/SF tumors in the C3H/HeJ mice by 41% as compared to control groups (P \ .01) ( Figure 3) . Plain polymer or polymer 1 DC treatment showed no significant difference in tumor volume as compared to the control group (P . .05). In the overall ANCOVA model, the interaction effect was statistically significant (P \ .0001), indicating that the treatment groups exhibited different rates of tumor growth over time. Our data show that our CCL21-secreting polymer is more effective against head and neck cancer than the plain polymer plus CCL21 given as an intratumoral bolus injection twice weekly.
DC-CCL21 Recruits DCs and T Cells and Inhibits Treg Cells at the Tumor Site
Animals treated with DC-CCL21 polymer exhibited a significant increase in the frequency of CD4 1 T cells and CD11c 1 DCs, as well as a marked decrease in CD4 1 CD25 1 regulatory T cells infiltrating the tumor sites ( Figure 4) . These data suggest that the antitumor effect of polymer-based DC-CCL21 treatment may, at least partially, be due to enhanced immune activity around the tumor site.
DC-CCL21 Polymer Inhibits Epithelial-to-Mesenchymal Transition in HNSCC Tumors
We sought to investigate the effect of DC-CCL21 polymer on epithelial-to-mesenchymal transition (EMT), a potential mechanism of metastasis. Tumor samples were harvested 12 days after implantation and were analyzed by immunoblotting against EMT markers. Epithelial markers, including Ecadherin, beta-catenin, and gamma-catenin, were increased, whereas the mesenchymal marker vimentin was decreased in the DC-CCL21 polymer-treated tumors ( Figure 5) . These data suggest that DC-CCL21 polymer treatment may lead to a less mesenchymal status that attenuates tumor invasion and, by promoting an epithelial phenotype, can also sensitize tumors to other forms of therapy. 
Discussion
We have developed a modular drug delivery device that reproducibly reduces tumor growth and enhances the efficacy of RT in vivo after partial tumor resection. We have used this partial tumor resection model in the mouse, replicating the difficult situation that we see in our patients in which the entire tumor is not resectable. The device we have developed is a flexible sheet that is designed to be applied intraoperatively to the surgical bed after removing or debulking the tumor and is engineered to adapt and adhere to the surgical resected tissue contours.
The combined use of radiotherapy and chemotherapy has been effective in improving the therapeutic index of radiation therapy for a variety of human cancers. [15] [16] [17] [18] [19] Our data show that our cisplatin-secreting polymer is more effective against head and neck cancer than the plain polymer plus cisplatin given as an intratumoral bolus injection. This enhanced antitumor activity is likely due to a more durable sustained release of cisplatin from the polymer platform increasing the interaction time with the tumor cells.
An additional benefit of this polymer system includes prophylaxis against tumor recurrence following resection. Viable squamous cell carcinoma (SCC) cells have been recovered from the surgical wound following neck dissection and were shown to be capable of growing as colonies in vitro; theoretically, these may implant and cause cancer recurrence. 20 Therefore, exposing such cells to this polymer system in combination with external beam radiation therapy, before they implant (while they are isolated and fragile), may decrease the chance of implantation.
Another attractive addition to our modular platform is the concept of polymer delivery of immunomodulators, which will increase the efficiency of tumor cell killing by the host's immune system. Patients with HNSCC have been well documented to exhibit local immunosuppression with depressed T-cell-mediated responses as well as depressed NK cell and antibody-dependent cell cytotoxic effects. 21 The major limitation for the clinical use of cytokines is the lack of a simple and effective protocol for the local and sustained delivery of cytokines to the tumor milieu.
We are aware of the results of other groups who have reported that secretion of CCL21 by HNSCC cells and by other paracrine sources can combine to promote activation of CCR7 prosurvival signaling associated with tumor progression. 22, 23 We feel that the seeming disparity in the data may be explained by physiologic versus pharmacologic doses of CCL21. Our efforts to produce effective cancer therapy focus on methods to address the deficits in the tumor microenvironment. To restore tumor antigen presentation and antitumor effector activities, we are using CCL21 (secondary lymphoid chemokine [SLC]), which is known to recruit dendritic, T, NK, and NKT cells. [24] [25] [26] [27] [28] [29] CCL21 may be distinctly advantageous because of its capacity to elicit a type I cytokine response in vivo. 30 Our group has demonstrated previously that CCL21 administered intratumorally elicits potent antitumor responses in murine cancer models. [30] [31] [32] [33] Vicari et al 34 substantiated our findings in a colon cancer model. Arenberg et al 35 have also reported that CCL21 inhibits human lung cancer growth and angiogenesis in a mouse model.
We studied the efficacy of CCL21 in the immunomodulator layer of our polymer platform. We demonstrated for the first time that DCs are able to survive and secrete functional CCL21 when grown in our polymer. The DC-CCL21 secreting polymer significantly reduces tumor burden, recruits dendritic and T cells while inhibiting Treg cells at the tumor site, and effectively inhibits EMT in HNSCC tumors.
We have designed and synthesized a biocompatible modular polymer platform that may be useful in treating patients with advanced or recurrent HNSCC. Our polymer wrap is biocompatible, is slowly degradable, and can serve as a platform to deliver immunomodulators and chemotherapeutic agents so as to most effectively kill tumor cells in the proximity of the polymer application. This polymer wrap is designed to be applied intraoperatively to the surgical bed after removing or debulking the tumor, thus allowing for enhanced postoperative radiation treatment and also functioning as a platform for the delivery of immunomodulators. Our work herein demonstrates that the polymer system is well tolerated and that CCL21, and cisplatin therapy combined with RT, generates a potent antitumor immune response against HNSCC.
Although the polymer used herein is currently used in FDA-approved devices, and both the intact polymer and its degradation products are known to be well tolerated in humans, the exact polymer-tissue interactions in the vicinity of a dynamic tumor environment are unknown. In this current work, we did not explicitly evaluate biocompatibility in such an environment and instead focused on demonstrating the overall utility of this modular approach. Now that feasibility has been demonstrated, the next step of our research program is to optimize the polymer platform to improve handling, cell delivery, and drug delivery.
The modular nature of this polymer platform provides an elegant approach to future investigations, allowing us to seek out specific molecular targets. This enables us to dissect underlying mechanisms of immune activation, which will in turn help us design additional strategies to block the inactivation and death of the cytotoxic effectors in patients with aggressive HNSCC. We will be able to build polymers that specifically target each patient's tumor as we can profile the tumors and then target them selectively on the polymer platform. As more combinations of the polymer platform are developed, this device may play an important role in the armamentarium against oral and head and neck SCCA, as well as many other cancers and human diseases. Once this polymer platform is optimized in an in vivo model, we will plan for the ultimate validation in the context of a prospective trial in patients with advanced or recurrent HNSCC.
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